Greyson International Inc. Garners Investor Interest in a series of Financial Presentations Pre-empting an Investor Conference
COCONUT CREEK, Fl. – Nov. 6, 2013- Greyson International Inc. (OTC Pink Sheets: GYSN), developer of an innovative patented trans-dermal and topical delivery emulsion targeting the multi-billion dollar anti-aging and OTC pharmaceutical industries, unveiled details about the technology as well as business plans and market potential in a three-city series of financial presentations. The multimedia presentation delivered by Greyson Marketing Director, Tia Castle reveals the science behind Trilexon® technology and explains the vast applications in the pharmaceutical and anti-aging market. A sixty-second preview clip of the presentation is also available which highlights how Trilexon® increases dermal permeation of anti-aging and/or topical pharmaceutical ingredients.
Tony Schor of Investor Awareness, director of the tri-city series remarked, “Now that the Company has a patent for Trilexon and is prepared to launch product, we felt it was the right timing to begin to tell the Greyson story to the financial community thru a series of financial presentations. We look forward to continuing our efforts in generating exposure and awareness on behalf of Greyson across the Country.”
“I felt this presentation explains the technology to both a lay and medical audience. But more importantly, I saw the light bulb go on when the audience of investors realized the enormous potential” said Tia Castle, Greyson International Marketing Director and Spokeswoman. She also added that an investor conference call will take place on Nov. 21, 2013 at 4:15 EST. A reminder press release will be issued to announce details and the call in phone number.
Harvey Tauman, CEO of Greyson Inc. commented, “Our diligence in attaining a patent and test marketing Trilexon® has us on the verge of exploding into the market place as supported by the science you will see explained in this presentation. I am very proud to announce that our team will launch the new product line in the first quarter of 2014.” Greyson International recently hired consultant Joe Bovino, Esq., to head their pharmaceutical licensing division. Joe has extensive relationships in the pharmaceutical industry having brokered many licensing deals for various companies.
About Greyson International, Inc.
Greyson’s primary focus is on its recently patented Trilexon® delivery system. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International Inc. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.
This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.
Greyson International Inc.
Harvey Tauman, 954-482-0497
Chief Executive Officer